To the Editor: In the April 2009 issue of the Journal, David A. Brent, M.D., et al. (1) examined predictors of suicidal adverse events in the treatment of selective serotonin reuptake inhibitor (SSRI) resistant depression in adolescents. The authors found that adjunctive use of benzodiazepines in a small patient group (N=10 [3% of the total sample]) was associated with a higher rate of both suicidal and non-suicidal self-injury. They concluded that the disinhibitory effects of benzodiazepines may lead to increased risk-taking behavior. This finding was reiterated in an accompanying editorial (2).
We suggest that this finding in such a small subgroup more likely represents a selection bias. Patients with comorbid anxiety disorders who have a higher risk of suicidal behaviors (3) are more likely to require adjunctive pharmacological treatment. Benzodiazepines may also have been prescribed for high levels of distress or agitation in this subgroup, which would also lead to an increase in self-harming behaviors. Given the small sample size and lack of information about comorbid diagnoses, the authors’ conclusion cannot be generalized to the population as a whole.
Dr. Cooney has served on the speaker’s bureau for Eli Lilly, GlaxoSmithKline, and Pfizer; and he has served on an advisory panel for Servier. Dr. Moore reports no competing interests.
This letter (doi: 10.1176/appi.ajp.2009.09050639) was accepted for publication in June 2009.